Dear Colleague,

After the huge success of our 3rd edition of CTAD 2010 last November in Toulouse, France, we are proud to present our exciting final program for this 4th edition of Clinical Trials on Alzheimer’s Disease sponsored by the UC San Diego School of Medicine.

This year’s CTAD in San Diego, USA will once again bring the current leaders involved in clinical trials to appreciate the full spectrum of AD from an asymptomatic stage through dementia, discuss the development of the next generation of Alzheimer’s disease treatments as well as learn to harmonize the various neuroimaging techniques and their analyses.

Alzheimer’s disease is one of the most important health challenge worldwide. This conference will also focus on new results, actual and future methodological issues, disease-modifying outcomes, biomarkers, fundamental research, new therapeutics and impact on the Healthcare economy.

CTAD is the perfect opportunity to hear about the clinical experiences of international teams, exchange with your peers on the difficulties and challenges of Alzheimer’s disease and take home some hands-on therapeutic and methodological tools to improve and reinforce your AD clinical trials teams.

Looking forward to seeing you in San Diego!

Paul Aisen - Jacques Touchon - Bruno Vellas - Michael Weiner
CONTENTS

Program ........................................................................................................................................ p. 2 - 15
  Program at a glance .................................................................................................................. p. 2 - 3
  Thursday, November 3rd ........................................................................................................... p. 4 - 7
  Friday, November 4th .............................................................................................................. p. 8 - 11
  Saturday, November 5th ......................................................................................................... p. 12 - 14
Posters ....................................................................................................................................... p. 15 - 21
Congress Venue ............................................................................................................................ p. 22
Registration & Accommodations ................................................................................................. p. 23
Continuing Medical Education ................................................................................................. p. 24 - 25
  Faculty List .............................................................................................................................. p. 26 - 28
  Disclosure summary .............................................................................................................. p. 29 - 30
Acknowledgments ....................................................................................................................... p. 31
### Thursday, November 3rd

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 - 08.15 a.m</td>
<td>WELCOME</td>
</tr>
<tr>
<td>08.15 - 08.45 a.m</td>
<td>OPENING KEYNOTE</td>
</tr>
<tr>
<td>08.45 - 09.45 a.m</td>
<td>Symposium 1: Neuroscience-based Cognitive Assessments to Detect the Preclinical Phase of Alzheimer’s Disease</td>
</tr>
<tr>
<td>09.45 - 10.45 a.m</td>
<td>Symposium 2: The Alzheimer’s Prevention Initiative: Overview and Progress</td>
</tr>
<tr>
<td>10.45 - 11.15 a.m</td>
<td>Coffee Break and poster sessions</td>
</tr>
<tr>
<td>11.15 - 12.15 p.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>01.15 - 02.15 p.m</td>
<td>Symposium 3: Improving Measurement Methodology To Detect Treatment Effect In Clinical Trials</td>
</tr>
<tr>
<td>02.15 - 03.30 p.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>04.00 - 05.30 p.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>05.30 - 06.00 p.m</td>
<td>Coffee Break and poster sessions</td>
</tr>
<tr>
<td>06.15 p.m</td>
<td>Bus departure to the reception</td>
</tr>
<tr>
<td>06.15 - 09.00 p.m</td>
<td>WELCOME RECEPTION OFFSITE</td>
</tr>
</tbody>
</table>

All presentations are held in the Presidential Ballroom

**Program at a Glance**

- **San Diego, CA - US Grant Hotel**

- Presidential Ballroom
- Celestial Ballroom
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, November 4th</td>
<td></td>
</tr>
<tr>
<td>08.30 - 09.45 a.m</td>
<td>Symposium 4: Event-Related Potential Biomarkers for Early Diagnosis and Treatment Trials of Alzheimer’s Disease</td>
</tr>
<tr>
<td>09.45 - 10.30 a.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>11.00 - 12.00 p.m</td>
<td>Symposium 5: Are the new AD diagnostic criteria helpful in clinical trials?</td>
</tr>
<tr>
<td>12.00 - 01.00 p.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>02.00 - 03.30 p.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>03.30 - 04.30 p.m</td>
<td>Symposium 6: Conversion from MCI to dementia: the weight, quality and reliability of the evidence</td>
</tr>
<tr>
<td>05.00 - 06.00 p.m</td>
<td>Symposium 7: Measuring the Earliest Symptoms of Mild Cognitive Impairment</td>
</tr>
<tr>
<td>Saturday, November 5th</td>
<td></td>
</tr>
<tr>
<td>08.00 - 12.00 p.m</td>
<td>Presidential Ballroom AB: Focus session: Clinical Trials in Frontotemporal Degeneration and Related Disorders</td>
</tr>
<tr>
<td>10.30 - 12.00 p.m</td>
<td>Presidential Ballroom CD: Focus session: Continued</td>
</tr>
<tr>
<td>08.00 - 9.00 a.m</td>
<td>Symposium 8: Novel Conceptual Models of Dementia (NCMD)</td>
</tr>
<tr>
<td>9.00 - 10.00 a.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>10.30 -11.30 a.m</td>
<td>Symposium 9: Amyloid-Related Imaging Abnormalities in Amyloid-Modifying Therapy Research</td>
</tr>
<tr>
<td>11.30 - 12.00 p.m</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
</tbody>
</table>
**Thursday, November 3rd**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 - 08.15 a.m</td>
<td><strong>WELCOME</strong></td>
</tr>
</tbody>
</table>
| 08.15 - 08.45 a.m | **OPENING KEYNOTE**: The evolution of AD trials  
*P.Aisen, ADCS, UC San Diego, USA* |
| 08.45 - 09.45 a.m | **Symposium 1**: Neuroscience-based Cognitive Assessments to Detect the Preclinical Phase of Alzheimer’s Disease  
- Eyelink Classical Conditioning: A Model System-Based Measure for the Early Detection of Alzheimer’s Disease  
- Translational Assessment of Memory for the Early Identification of Cognitive Impairment  
- A Scalable Unobtrusive Home-Based Monitoring System to Assess Everyday Functional Ability Prior to Mild Cognitive Impairment  
*Chair: D.Woodruff-Pak, Temple University, Philadelphia, USA*  
*Speakers: J.Raber, J.Kaye, Oregon Health Science University, USA* |
| 09.45 - 10.45 a.m | **Symposium 2**: The Alzheimer’s Prevention Initiative: Overview and Progress  
*P.Tariot, J.Langbaum, A.Fleisher, Banner Alzheimer’s Institute, Phoenix, USA* |
| 10.45 - 11.15 a.m | Coffee Break and poster sessions                                                          |
| 11.15 - 12.15 p.m | **ORAL COMMUNICATIONS**                                                                  |
| 11.15 - 11.30 a.m | **O1** - Optimizing The ADAS-Cog For MCI And Early AD  
*N.Raghavan, PhD, Johnson and Johnson, USA*  
*M.N.Samtani, PhD, M.Farnum, PhD, E.Yang, PhD, V.Lobanov, PhD, G.Novak, MD, V.Narayan, PhD, A.DiBernardo, MD* |
| 11.30 - 11.45 a.m | **O2** - Plasma amyloid β concentrations and prognosis in incident dementia cases: the prospective Three-City Study  
*A.Gabelle, Montpellier University Hospital, France*  
| 11.45 - 12.00 p.m | **O3** - Bayesian data mining with ensemble learning predicts the conversion from mild cognitive impairment to Alzheimer’s disease  
*R.Chen (1), K.Young (2), L.L.Chao (2), B.Miller (2), K.Yaffe (2), M.W.Weiner (2), E.H.Herskovits (1)*  
(1) Department of Radiology, University of Pennsylvania, Philadelphia, PA. (2) Center for Imaging of Neurodegenerative Diseases, UCSF VA Medical Center, San Francisco, CA |
Thursday, November 3rd  Continued

12.00 - 12.15 p.m  O4 - Validation of the Placebo Group Simulation Approach (PGSA) Using a Large NACC Data Set
   R. Spiegel, Basel University Hospital, Switzerland
   M. Berres, A. R. Miserez, A. U. Monsch

12.15 - 01.15 p.m  Lunch break and poster sessions

01.15 - 02.15 p.m  Symposium 3: Improving Measurement Methodology To Detect Treatment Effect In Clinical Trials
   - Generative Cognitive Processing Modeling Methods to Measure Treatment Effect
   - Use of a subset of the ADAS-cog and MMSE items substantially improves the sensitivity to decline in Mild AD and MCI patients
   - Area under the curve analysis to compare treatment group differences: Actual vs. Modeled Results
   Chair: W. Shankle, Medical Care Corporation, Newport Beach, USA
   Speakers: A. Atri, Massachusetts General Hospital, Boston, USA, S. Hendrix, Pentara Corporation, Salt Lake City, USA

02.15 - 03.00 p.m  ORAL COMMUNICATIONS
   Moderators: C. Sampaio, Faculty of Medicine, Lisbon, Portugal, D. Galasko, University of California, San Diego USA

02.15 - 02.30 p.m  O5 - NILVAD: An investigator driven European multi-centre placebo-controlled phase III trial of NILVADIPINE, a calcium channel blocker, in mild to moderate Alzheimer’s disease
   B. Lawlor, St. James’s Hospital, Dublin, Ireland

02.30 - 02.45 p.m  O6 - Meta-analysis of composite endpoints in clinical trials of Alzheimer’s disease
   M. Riepe, Charité Medical University, Berlin, Germany
   D. Wilkinson, H. Furstl, A. Brieden

02.45 - 03.00 p.m  O7 - A Randomized Controlled Alzheimer’s disease Prevention Trials Evolution into an Exposure Trial
   R. J. Kryscio (1,2), E. L. Abner (1), M. Mendiondo (1,2), A. Caban-Holt (3), B. C. Dennis (4), C. R. Runyons, F. A. Schmitt (1,5), J. J. Crowley (6)
   for the SELECT Investigators
   (1) Sanders-Brown Center on Aging, and Departments of Biostatistics, (2) Statistics, (3) Behavioral Science, (4) Neurology and Psychiatry, (5) Psychology, University of Kentucky, Lexington KY, USA, and Cancer Research and Biostatistics, Seattle WA, USA

03.00 - 03.15 p.m  O8 - Efficacy of a Nutriceutical Formulation on Cognitive Performance and Function in Persons with Mild Cognitive Impairment and Alzheimer’s Disease
   (1) University of Massachusetts Lowell, USA, (2) Framingham State Univ, (3) Heather Hoffmann (Knox College), (4) Univ of Maryland, (5) Worcester State Univ
**Thursday, November 3rd Continued**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 03.15 - 03.30 p.m | O9 - The efficacy of donepezil on a structural outcome (hippocampal atrophy) in the recently defined prodromal Alzheimer’s disease (AD) population characterized by a progressive amnestic syndrome of the hippocampal type  
  **B.Dubois** (1), **M.Chupin** (2), **B.Croisile** (3), **G.Louis Tisserand** (3), **J.Touchon** (4), **A.Bonafe** (4), **P.J.Ousset** (5), **A.Ameur** (6), **O.Rouaud** (7), **F.Ricolfi** (7), **A.Vighetto** (3), **F.Pasquier** (8), **C.Delmaire** (9), **M.Ceccaldi** (10), **N.Girard** (10), **S.Lehericy** (11), **I.Tonelli** (12), **F.Duveau** (12), **L.Garnier** (2), **M.Sarazin** (1), **D.Dormont** (2) And The Donepezil Hippocampus Study Group  
  (1) Institut de la mémoire et de la maladie d'Alzheimer (IMMA) Hopital de la Salpêtrière, Paris, France ; (2) Cognitive Neuroscience and Brain Imaging Laboratory, CNRS UPR640, Paris, France ; (3) Hopital Neurologique Pierre Wertheimer, Lyon, France ; (4) CHU, Guy de Chauliac, Montpellier, France ; (5) Hopital Casselardit, Toulouse, France ; (6) Clinique Pasteur, Toulouse, France ; (7) Hôpital général, Dijon, France ; (8) CHRU, clinique de Neurologie, Lille, France ; (9) Hôpital Roger Salengro, Lille, France ; (10) Hopital de la Timone, Marseille, France ; (11) Inserm U610 and CENIR, Neuroimaging Unit, Paris, France ; (12) Eisai SAS, La Defense 2 cedex, France |
| 03.30 - 04.00 p.m | Coffee Break and poster sessions |
| 04.00 - 05.30 p.m | ORAL COMMUNICATIONS  
  Moderators : C.Sampaio, Faculty of Medicine, Lisbon, Portugal, D.Galasko, University of California, San Diego USA  
  **04.00 - 04.15 p.m**  
  O10 - Preclinical Behavioral Detection of Alzheimer’s Disease  
  **S.Karantzoulis** (1), **H.Lau** (1), **C.E.Myers** (2), **R.P.Kesner** (3), **S.De Santi** (4,1), **A.Gurnani** (1), **H.Scharfman** (5,1), **S.H.Ferris** (1)  
  (1) New York University Langone Medical Center, NY ; (2) DVA New Jersey Health Care System, and Department of Psychology, Rutgers University ; (3) Department of Psychology, University of Utah ; (4) Bayer Healthcare Pharmaceuticals, Inc. ; (5) Nathan Kline Institute  
  **04.15 - 04.30 p.m**  
  O11 - A pharmacogenetic-assisted clinical trial to assess the delay of cognitive impairment of the Alzheimer’s disease type  
  **A.Roses**, Duke University, USA  
  **04.30 - 04.45 p.m**  
  O12 - A Randomized Clinical Trial of an inhibitor of RAGE-A-beta interactions in patients with mild to moderate AD  
  **D.Galasko**, University of California, San Diego USA  
  C.Van Dyck, M.Sabbagh, Thomas, RT, Aisen, PS, J.Kupiec, J.Bell, for the Alzheimer’s Disease Cooperative Study  
  **04.45 - 05.00 p.m**  
  **S.D.Edland**, University of California, San Diego USA  
  M.Colin Ard |
Thursday, November 3rd  

**05.00 - 05.15 p.m**  
**LB11** - Cognitive Decline in the Elderly Population of the GuidAge Study – A 5-Year Follow up of Subjects with Memory Complaints. Is it possible to identify subjects at risk for decline  
P.J. Ousset (1,2,3), S. Andrieu (1,2,3,5), H. Mathiex-Fortunet (4), P. Garnier (4), J. Touchon (6), B. Vellas (1,2,3)  
(1) INSERM U 1027, Toulouse, France; (2) University of Toulouse III, Toulouse, France; (3) Gerontopole, Toulouse University Hospital, Toulouse, France; (4) Ipsen, Boulogne, France; (5) Department of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France; (6) Montpellier University Hospital

**05.15 - 05.30 p.m**  
**LB12** - Representations and practices of prevention in elderly populations: investigating acceptance to participate in and adhesion to an intervention study for the prevention of Alzheimer’s disease (ACCEPT study)  
S. Andrieu (1,2,3,4), N. Coley (1,2), V. Gardette (1,2,3), J. Subra (5), S. Oustric (1,2,5), G. A. Andrieu (1,2,3,4), B. Vellas (1,2,3)  
(1) INSERM U 1027, Toulouse, France; (2) University of Toulouse III, Toulouse, France; (3) Gerontopole, Toulouse University Hospital, Toulouse, France; (4) Department of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France; (5) Department of Primary Care, Toulouse University Hospital, Toulouse, France

**05.30 - 06.00 p.m**  
**CLOSING KEYNOTE** : Pre-Clinical AD: «What Do the Data Show?»  
R. Petersen, Mayo Clinic Alzheimer’s Disease Research Center, Rochester, MN, USA

**06.15 p.m**  
Buses departure to the reception

**06.30 - 09.00 p.m**  
**WELCOME RECEPTION**: Hosted by the Alzheimer’s Disease Cooperative Study at the University of California San Diego, CTAD2011 welcomes us to an evening of networking and relaxation overlooking the San Diego Bay.
Friday, November 4th

08.30 - 09.45 a.m  Symposium 4 : Event-Related Potential Biomarkers for Early Diagnosis and Treatment Trials of Alzheimer’s Disease

Chairs : L.Schneider, University of Southern California, A.Budson, Boston University, USA

Speakers :

- Use of ERPs for Clinical Trials of Preclinical AD/MCI/AD, J.Olichney, UCSB, USA
- ERPs in Animal Models: Implications for Translational AD Clinical Trials, S.Leiser, Lundbeck Research USA
- ERP Biomarkers as Primary Endpoints in an Industry-Sponsored Phase II AD Clinical Trial, M.Segerdahl, AstraZeneca R&D, USA
- Can ERPs predict the progression of MCI patients?, K.Bennys, Montpellier University Hospital, France

09.45 - 10.30 a.m  ORAL COMMUNICATIONS

Moderators : B.Vellas, Toulouse University Hospital, France, P.Scheltens, Alzheimer Centrum, The Netherlands

09.45 - 10.00 a.m  LB1 - MRI Features of Asymptomatic Amyloid Related Imaging Abnormalities-Edema (ARIA-E) Identified at Baseline in AD Study Cohorts, and MR Artifacts Which Mimic ARIA-E

J.Barakos, MD (1,2), C.Carlson, PhD (3), W.Estergard, PharmD (3), J.Oh, PhD (1), J.Suhy, PhD (1), C.Jack, MD (4), E.Siemers, MD (3)

(1) Synarc, San Francisco, CA ; (2) California Pacific Medical Center, San Francisco, CA ; (3) Lilly Research Laboratories, Indianapolis, IN ; (4) Mayo Clinic, Rochester, MN

10.00 - 10.15 a.m  LB2 - Influence of CSF biomarkers on cognitive decline in an interrupted MCI-trial


(1) Department of Psychiatry, Charité - CBF, Berlin ; (2) Center for Geriatric Medicine and Gerontology, University Hospital Freiburg ; (3) Department of Psychiatry, University Göttingen ; (4) Department of Psychiatry, Ludwig Maximilian University Munich ; (5) Department of Psychiatry, University Bonn ; (6) Department of Psychiatry, University Erlangen ; (7) Department of Psychiatry, University Düsseldorf ; (8) Central Institute of Mental Health, Mannheim

10.15 - 10.30 a.m  LB3 - Title to be announced

P.Scheltens, Alzheimer Centrum, The Netherlands

10.30 - 11.00 a.m  Coffee Break and poster sessions
11.00 - 12.00 p.m **Symposium 5 : Are the new AD diagnostic criteria helpful in clinical trials?**
- Why do we need new criteria?
- Clinical criteria for MCI, AD type
- Imaging Criteria
- Are CSF criteria helpful?

**Chairs : A.Korczyn, Tel Aviv University Medical School, Israel, L.Schneider, University of Southern California, USA, R.Sperling, Brigham and Women’s Hospital, Massachusetts General Hospital, Boston, USA**

12.00 - 01.00 p.m **ORAL COMMUNICATIONS**

**Moderators : R.McShane, University of Oxford, UK, M.Grundman, UC San Diego, USA**

12.00 - 12.15 p.m **O14 - Identifying Middle-aged Adults for Participation in AD Prevention Trials Using Dementia Risk Scores vs. Cerebrospinal Fluid Biomarker Cutoffs**
C.Carlsson, University of Wisconsin, USA

12.15 - 12.30 p.m **O15 - Amyloid deposition and white matter lesions in cognitively healthy elderly**
L.Glodzik, NY University Medical Center, USA
H.Rusinek, L.Mosconi, Y.Li, E.Pirraglia, M.Cummings, J.Murray, S.Williams, C.Randall, S.Vallabhajolusa, M.de Leon

12.30 - 12.45 p.m **O16 - Application of Item-Response Theory (IRT) to the Detection of Treatment Effects on Functional Outcomes in Alzheimer’s Disease**
C.Ard, University of California, San Diego
S.D.Edland Ph.D

12.45 - 01.00 p.m **O17 - Responders to ELND005 (Scyllo-inositol) in an Alzheimer’s Disease Study of 78 Weeks Duration: Analysis of their Clinical, v-MRI, and CSF Biomarker Characteristics**
A.Porsteinsson (1) MD, R.Sperling (2) MD, S.Salloway (3) MD, G.Crans (4) PhD, C.Hernandez (5) PhD, S.Abushakra (6) MD
(1) University of Rochester Medical Center, Rochester NY, (2) Brigham and Women’s Hospital, Boston MA, (3) Butler Hospital/Brown University, Providence RI, (4) Elan Pharmaceuticals, S. San Francisco

01.00 -02.00 p.m **Lunch Break and poster sessions**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.00 - 02.15 p.m</td>
<td>O18</td>
<td>A 78-week Phase 2 Study of ELND005 (Scyllo-inositol) in Alzheimer’s Disease: Clinical Outcomes by Various MMSE Definitions of Mild Disease</td>
<td>S.Salloway (1) MD, A.Porsteinsson (2) MD, G.Crans (3) PhD, C.Hernandez (3) PhD, S.Abushakra (3) MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1) Butler Hospital/Brown University, Providence RI, (2) University of Rochester Medical Center, Rochester NY, (3) Elan Pharmaceuticals, S. San Francisco</td>
</tr>
<tr>
<td>02.15 - 02.30 p.m</td>
<td>O19</td>
<td>Amyloid Burden and Neuropsychological Test Performance in Cognitively Normal First-Degree Relatives at Varying Genetic Risk for Alzheimer’s Disease</td>
<td>C.Van Dyck, A.Bruck, N.M.Barcelos, B.Planeta-Wilson, A.L.Benincasa, M.G.MacAvoy, Y.S.Ding, J.Gelernter, R.E.Carson, Yale University School of Medicine</td>
</tr>
<tr>
<td>02.30 - 02.45 p.m</td>
<td>O20</td>
<td>Strategies of Enrichment and Stratification for Efficient Alzheimer Disease Clinical Trials Using Longitudinal Structural MRI Outcome Measures</td>
<td>D.Holland, University of California, San Diego, USA, L.K.McEvoy, A.M.Dale</td>
</tr>
<tr>
<td>02.45 - 03.00 p.m</td>
<td>O21</td>
<td>Targeting vascular activation: a novel therapeutic strategy for Alzheimer’s disease</td>
<td>P.Grammas, Texas Tech University Health Science Center, USA, L.Yin, A.Sanchez, M.Evola, A.Young, Garrison Institute on Aging, Texas Tech University Health Science Center, Lubbock, TX</td>
</tr>
<tr>
<td>03.00 - 03.15 p.m</td>
<td>O22</td>
<td>Disease-modification in MCI with homocysteine-lowering B vitamins slows atrophy of particular brain regions: the VITACOG trial</td>
<td>G.Douaud (1), H.Refsum (2), C.A.de Jager (2), K.Brady (2), R.Jacoby (2), S.M.Smith (1), A.D.Smith (2)</td>
</tr>
<tr>
<td>03.15 - 03.30 p.m</td>
<td>LB4</td>
<td>AFFITOPE® Alzheimer vaccines – Results from clinical phase I support the further clinical development of AFFITOPE® AD02</td>
<td>A.Schneeberger, M.Mandler, F.Mattner, W.Schmidt, AFFIRIS AG, Vienna, Austria</td>
</tr>
</tbody>
</table>
Friday, November 4th  

03.30 - 04.30 p.m  
**Symposium 6 :** Conversion from MCI to dementia: the weight, quality and reliability of the evidence  
**Chair:** R.McShane, Cochrane Dementia and Cognitive Improvement Group, University of Oxford, UK  
- Systematic review of longitudinal studies of amyloid PET ligands  
  N.Smailagic, CDCIG, University of Cambridge, UK  
- Reporting standards in diagnostic test accuracy studies in the dementia literature: a review and recommendations  
  A.Noel-Storr, CDCIG, University of Cambridge, UK  
- Reliability of the “dementia outcome”: what can we learn from Stroke?  
  T.Quinn, CDCIG, University of Oxford, UK  

04.30 - 05.00 p.m  
Coffee Break and poster sessions

05.00 - 06.00 p.m  
**Symposium 7 :** Measuring the Earliest Symptoms of Mild Cognitive Impairment  
- The Signal from Trials: Perceived Deficits  
- Industry Partnerships in Pre-Competitive Measure Development in MCI  
- Findings from the Cognition Working Group of the PRO Consortium  
**Chair:** D.Miller, L.Frank, United BioSource Corporation, USA  
**Speakers:** R.Doody, Baylor College of Medicine, C.Leibman, Janssen Alzheimer Immunotherapy, USA  
W.Lenderking, United BioSource Corporation, USA
### Saturday, November 5th

#### Presidential Ballroom AB

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 - 12.00 p.m</td>
<td>Focus session (8.00 a.m - Noon): Clinical Trials in Frontotemporal Degeneration and Related Disorders</td>
</tr>
</tbody>
</table>

**Chair:** A.Boxer, University of California, San Francisco, USA  

(1) University of California, San Francisco  
(2) Cleveland Clinic Lou Ruvo Brain Institute  
(3) Allon Therapeutics  
(4) Bristol Myers Squibb  
(5) Mayo Clinic, Rochester  
(6) University of British Columbia  
(7) Columbia University  
(8) Emory University

#### Presidential Ballroom CD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 08.00 - 09.00 a.m | Symposium 8: Novel Conceptual Models of Dementia (NCMD)  
Z.Khachaturian, PAD2020 Potomac, USA |

#### ORAL COMMUNICATIONS

**Moderator:** P.J.Ousset, Toulouse University Hospital, France

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 09.00 - 09.15 a.m | LB5 - A multi-center, randomized, double-blind, placebo-controlled trial of vitamin E in aging persons with Down syndrome  
M.Sano, Mount Sinai School of Medicine, USA  
A.Dalton, PhD, P.Aisen, MD, W.Y.Tsai, PhD, H.Andrews, PhD |
| 09.15 - 09.30 a.m | LB6 - Tesamorelin, a growth hormone-releasing hormone analogue, improves cognitive function in MCI and healthy aging: results of a randomized controlled trial  
L.Baker, VAPSHCS, Seattle, USA  
S.M.Barsness, S.Borson, G.R.Merriam, S.D.Friedman, S.Craft, M.V.Vitiello |
### Continued

<table>
<thead>
<tr>
<th>Presidential Ballroom AB</th>
<th>Presidential Ballroom CD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Focus session continues</strong></td>
<td></td>
</tr>
</tbody>
</table>

**09.30 - 09.45 a.m**

**LB7** - Phase II clinical trial of metformin in amnestic MCI: rationale, methods, and barriers and enablers of successful recruitment  
T.Perez, MD, S.Thareja, E.Arana, H.Chang, E.Bagiela, PhD, J.A.Luchsinger, MD MPH  
*Columbia University Medical Center, New York, NY*

**09.45 - 10.00 a.m**

**LB8** - The Effects of ELND005 (Scyllo-inositol) on Emergence of New Neuropsychiatric Symptoms in a 78-Week Phase 2 Study in Mild and Moderate Alzheimer’s Disease  
C.Lyketsos, *The Johns Hopkins Bayview Medical Center, Baltimore, USA*  
S.Abushakra MD, P.Tariot MD, G.Crans PhD, C.Hernandez PhD, J.Cedarbaum MD

**10.00 - 10.30 a.m**  
Coffee Break and poster sessions
Continued

### Presidential Ballroom AB

**10.30 - 12.00 p.m**

**Focus session:** Clinical Trials in Frontotemporal Degeneration and Related Disorders

### Presidential Ballroom CD

**10.30 - 11.30 a.m**

**Symposium 9:** Amyloid-Related Imaging Abnormalities in Amyloid-Modifying Therapy Research

- Targeting beta-amyloid in the brain
  - *Chair:* J. Touchon, Montpellier University Hospital, France
- Alzheimer’s Association Research Roundtable recommendations on ARIA in Amyloid Modifying Therapeutic Trials Clinical: perspective and recommendations
  - M. Carrillo, Alzheimer’s Association, Chicago, IL, USA
- Understanding the pathophysiology of ARIA
  - S. Salloway, Butler Hospital, RI, USA
- Overview of experimental evidence and insights from nonclinical data
  - G. Kinney, Janssen Al San Francisco, CA, USA

### ORAL COMMUNICATIONS

**Moderators:** Z. Khachaturian, PAD2020 Potomac, USA

**11.30 - 11.45 p.m**

**LB9** - Responder Analyses from a Phase 2 Placebo-Controlled Study of ELND005 (Scyllo-inositol) in Mild and Moderate Alzheimer’s Disease

A. Porsteinsson (1) MD, R. Sperling (2) MD, G. Crans (3) PhD, C. Hernandez (3) PhD, S. Abushakra (3) MD

(1) University of Rochester Medical Center, Rochester NY, (2) Brigham and Women’s Hospital, Boston MA, (3) Elan Pharmaceuticals, S. San Francisco

**11.45 - 12.00 p.m**

**LB10** - Towards retinoid therapy for Alzheimer’s disease

K. Shudo, Itsuu Laboratory, Tokyo, Japan

H. Fukasawa, M. Nakagomi, N. Yamagata, Y. Amano, T. Miki
SCIENTIFIC POSTERS

They will be displayed all day long in the Celestial Ballroom during the entire event. You will get a chance to meet with their authors during coffee breaks and lunches taking place in the Celestial Ballroom.

For your convenience posters are classified by themes and numbered accordingly:

<table>
<thead>
<tr>
<th>THEMES</th>
<th>P1 through P13</th>
<th>P14 through P20</th>
<th>P21 through P29</th>
<th>P30 through P38</th>
<th>P39 and P40</th>
<th>P41 and P42</th>
<th>P43 and P44</th>
<th>p.16 to 17</th>
<th>p.17 to 18</th>
<th>p.18 to 19</th>
<th>p.19 to 20</th>
<th>p.20</th>
<th>p.20</th>
<th>p.21</th>
</tr>
</thead>
</table>
### POSTERS

#### Biomarkers AD/Imaging

<table>
<thead>
<tr>
<th>Posters</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>Brain Metabolite Changes in Mild and Moderate Alzheimer’s Disease: Correlation with v-MRI and Clinical Measures of Disease Severity</td>
<td>S. Abushakra, G. Crans PhD, S. Narayanan PhD, E. Liang PhD, C. Hernandez PhD, D. Arnold MD</td>
</tr>
<tr>
<td>P2</td>
<td>The Scopolamine model, cognitive p300 potentials and quantitative EEG: from region-specific targets to biomarker of drug efficacy</td>
<td>P. Boeijinga, N. Pross, P. Danjou, L. Soufflet, E. Voltz, R. Barnouin</td>
</tr>
<tr>
<td>P3</td>
<td>The importance of S1-pocket of glutamate carboxypeptidase II in exerting Amyloid beta degradation activity</td>
<td>K. Hyunyoung Kim, S. Kyung Lee, M. J. Kim, S. Ick Park</td>
</tr>
<tr>
<td>P4</td>
<td>Event-Related Potential (ERP) &amp; Quantitative Electroencephalography (qEEG) Biomarkers for Alzheimer’s Disease: The COGNISION™ System</td>
<td>M. Kulkarni (1), D. A. Casey (2), G. A. Jicha (3), P. R. Solomon (4), P. M. Doraiswamy (5), D. A. Wolk (6), S. E. Arnold (6), C. D. Smith (3) (1) Neuronetrix; (2) University of Louisville, KY; (3) University of Kentucky, KY; (4) The Memory Clinic, VT; (5) Duke University; (6) University of Pennsylvania</td>
</tr>
<tr>
<td>P7</td>
<td>Dynamic Bayesian network modeling reveals altered trajectory interaction between hippocampus and the entorhinal cortex in mild cognitive impairment</td>
<td>E. Herskovits, R. Chen and the Alzheimer’s Disease Neuroimaging Initiative Department of Radiology, University of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>P8</td>
<td>Noninvasive assessment of drug binding site with positron emission tomography is useful in the prediction of the efficacy of cholinesterase inhibitor</td>
<td>N. Okamura, M. Kasuya, H. Ishikawa, N. Tanaka, Y. Funaki, R. Iwata, K. Meguro, K. Yanai</td>
</tr>
<tr>
<td>P9</td>
<td>Alzheimer’s disease biology of a 96 gene expression assay developed to aid in the diagnosis of the disease</td>
<td>A. Lonneborg, G. Grave, H. M. Andersen, L. Kristiansen, T. Lindahl, L. Roed, P. Sharma</td>
</tr>
</tbody>
</table>
### Clinical trials assessment tools

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| P11    | Clinical longitudinal study of inflammatory factors in plasma and PBMCs of patients with Alzheimer's disease: predictive value of cytokines | A.Julian (1)  
Co-authors: G.Page (1), T.Dantoine (5), P.Krolak-Salmon (6), G.Berrut (7), C.Hommet (8), O.Beauchet (9), O.Hanon (10), L.Blanchard (3), S.Brishoual (3), S.Ragot (3), M.Paccalin (1, 2, 3, 4)  
(1) Research Group on Brain Aging, EA 3808, University of Poitiers; Department of Geriatrics; (2) University Hospital Poitiers; (3) Centre d’Investigation Clinique INSERM 802; Research and Resource Memory Centers; (4) Poitiers; (5) Limoges; (6) Lyon; (7) Nantes; (8) Tours; (9) Angers; (10) Broca Paris, France |
| P12    | The Beta-amyloid pool in blood helps to distinguish between prodromal AD (probable) MCI and other MCI | P.Pesini  
Co-authors: V.Perez-Grijalba, I.Monleon, M.Boada, L.Tarraga, I.San-José, P.Pesini, M.Sarasa |
| P13    | 6-Biomarker algorithms identify Alzheimer's disease at high accuracy | M.Zellner  
Co-authors: A.Graf, R.Babeluk, M.Veiltinger, E.Umlauf  
Medical University of Vienna, Vienna, Austria |
| P14    | Age-expanded normative data for the Ruff 2&7 Selective Attention Test; Evaluating selective attention in older individuals for clinical trials | A.Caban-Holt  
Co-authors: E.Abner, MPH, R.Kryscio, Ph.D., B.Dennis, D.Psy, F.Schmitt, Ph.D |
| P15    | Variability in MMSE Scores Between Screening and Baseline Visits in 2 Large, Multi-National Alzheimer's Disease Study Programs: A Concern and Potential Solutions | D.Miller  
Co-authors: A.Young, MS (United BioSource Corporation, Wayne, PA, US), W.Estergard, PharmD, D.Henley, MD, K.Sundell, BS |
| P16    | Use of informant-reported web-based data collection to assess dementia symptoms: validation in relation to the Dependence Scale | K.Rockwood (1)  
Co-authors: A.Zeng (1), C.Liebman (2), A.Mitnitski (1)  
(1) DementiaGuide Inc., Halifax, NS Canada  
(2) Janssen Alzheimer Immunotherapeutics PLC, San Francisco, CA, USA |
| P17    | Comparison of motor performance in upper and lower extremities under dual-task patients with mild Alzheimer’s dementia | A.Wong  
Co-authors: C.Gung Memorial Hospital Taiwan R.O.C, S.W.Chou, MD, PhD, C.W.Wu, MD, C.Chang Huang, MD, M.C.Chiou, MD, H.C.Fung, MD, PhD |
| P18    | Framework for Patient Synchronization via ADAS-Cog 13 and its Consequences for Disease Progression Visualization and Clinical Trials | E.Yang  
Co-authors: M.Farnum, PhD, V.Lobanov, PhD, T.Schultz MS, N.Raghaban, PhD, M.N.Samtani, PhD, G.Novak, MD, V.Narayan, PhD, A.DiBernardo, MD |
| P19    | Microarray-based transcriptomic signatures to help improving the success rate of ad Clinical Trials | M.Pando  
Co-authors: P.Beurdeley, L.Desire, V.Kotraiah, M.Pando, I.Barber |
### POSTERS

#### Clinical trials assessment tools (Continued)

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P20</td>
<td>The Brief Episodic Memory Assessment: A new scale to measure the episodic memory in Alzheimer’s disease to complement new one-plus-one in vivo diagnosis strategy</td>
<td>C. Yavorsky, PhD, A. Khan, PhD, A. Defries, MA, M. Opler, MPH, PhD</td>
</tr>
</tbody>
</table>

#### Clinical trials methodology

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P21</td>
<td>Practice Effects in a Longitudinal, Multi-Center Alzheimer’s Disease Prevention Clinical Trial</td>
<td>E.L. Abner (2), A. Caban-Holt (4), M. Mendiondo (2,3), R.J. Kryscio (2,3), F.A. Schmitt (1,4,5), J.J. Crowley (6) for the SELECT Investigators</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(1) Sanders-Brown Center on Aging, and Departments of Neurology, (2) Biostatistics, (3) Statistics, (4) Behavioral Science, (5) Psychiatry &amp; Psychology, (6) University of Kentucky, Lexington KY, USA, and Cancer Research and Biostatistics, Seattle WA, USA</td>
</tr>
<tr>
<td>P22</td>
<td>Compliance with the requirements of anti-Alzheimer’s with the main recommendations issued in March 2008 HAS</td>
<td>A. Guérin (1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>L. Joffredo (2), A. Chevallier (1), FX Chedhomme (1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(1) Pharmacy unit; (2) Medical unit, Broca hospital, APHP Paris France</td>
</tr>
<tr>
<td>P23</td>
<td>Examining recruitment in a Phase II multisite industry-sponsored interventional trial in mild-to-moderate Alzheimer’s disease</td>
<td>J. Grill (1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. Elashoff, PhD (1), J. Hazel RN (2), R. Berman, MD (2), V. Coric, MD (2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(1) Mary Easton Center for Alzheimer’s disease Research at UCLA, Los Angeles, CA; (2) Bristol-Myers Squibb Research &amp; Development, Wallingford, CT</td>
</tr>
<tr>
<td>P24</td>
<td>Estimating sample sizes for predementia Alzheimer’s disease clinical trials based on the Alzheimer’s Disease Neuroimaging Initiative</td>
<td>L. Di, PhD (1,3), D. Elashoff, PhD (1,3), P. H. Lu, PsyD (1), O. Kohannim (2), L. Apostolova, MD (1), J. M. Ringman, MD (1), J. L. Cummings, MD (4), P. Thompson, PhD (2), and the Alzheimer's Disease Neuroimaging Initiative</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(1) Mary Easton Center for Alzheimer’s Disease Research; (2) Laboratory of Neuroimaging, Department of Neurology; (3) Department of Medicine Statistics Core, University of California, Los Angeles, David Geffen School of Medicine; (4) Lou Ruvo Institute for Brain Health, Cleveland Clinic, Las Vegas, NV</td>
</tr>
<tr>
<td>P25</td>
<td>What Promising Recruitment Strategies Promote Continued Participation in Alzheimer’s Disease Prevention Trials?</td>
<td>L. Jacobson, School of Medicine University of Wisconsin, Madison, WI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>H. M. Blazel, C. E. Gleason, S. C. Johnson, M. A. Sager, K. M. Paterson, S. Asthana, C. M. Carlsson CM</td>
</tr>
<tr>
<td>P26</td>
<td>Protocols from Hell: a review of difficulties in conducting clinical trials in Alzheimers Disease</td>
<td>R. Hogarth</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Kurle MD PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Division of Rehabilitation and Aged Care, Hornsby Ku-ring-gai Hospital, Hornsby, Australia</td>
</tr>
<tr>
<td>P27</td>
<td>Statistical Considerations for Designing a Longitudinal Clinical Trial in Early (Prodromal) Alzheimer’s Disease Subjects</td>
<td>Y. Peng</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Ryan</td>
</tr>
</tbody>
</table>
Clinical trials methodology (Continued)

P28 Which are the reasons to not include AD patients in clinical trials?
A.Rollin-Sillaire (1,2)
Co-authors : L.Breuilh (1,2), N.Jourdan (1, 2), F.Pasquier (1,2)
(1) Université Lille Nord de France, UDSL, EA 1046, Lille, France ; (2) Memory Clinic, Lille University Hospital, Lille, France

P29 Assessing reliability of distributed data entry of the adas-cog in a multicentered Clinical Trial
S.Walters
Co-authors : D.Gessert, M.Donohue, PhD., P.Aisen, MD.Alzheimer’s Disease Cooperative Study
Acknowledgements : T.Sather, M.Davis, E.J. Trinidad, I.Sim, L.Bouill, W.C.Liu

Treatment therapeutics for AD

P30 NPT001: A Novel Therapeutic Approach for Reducing Levels of Both Beta-Amyloid Plaques and Neurofibrillary Tangles in Alzheimer’s Disease
R.Fisher (1)

P31 Impact of initiation of treatment with Memantine or Cholinesterase Inhibitors (ChEI) on the use of Psychotropic Drugs: Analysis of RAMQ Database
J.Lachaine (1)
Co-authors : C.Beauchemin (1), A.Crochard (2), S.Bineau (3)
(1) Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada ; (2) Market Access Department, Lundbeck SAS, Issy-Les-Moulineaux, France ; (3) Global Outcomes Research Division, Lundbeck SAS, Issy-Les-Moulineaux, France

P32 Combination memantine with acetylcholinesterase inhibitor delays the admission of Alzheimer’s disease patients to nursing home: Cost-effectiveness analysis in France
J.Lachaine (2)
Co-authors : J.Touchon (1), C.Beauchemin (2), A.Crochard (3), B.Rive (4), S.Bineau (4)
(1) Faculty of Medicine, University of Montpellier, France ; (2) Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada ; (3) Market Access Department, Lundbeck SAS, Issy-Les-Moulineaux, France ; (4) Global Outcomes Research Division, Lundbeck SAS, Issy-Les-Moulineaux, France

P33 The tacrine derivative 7-MEOTA in the treatment of AD
O.Soukup (1,2)
Co-authors : J.Patocka (4), J.Zdarova-Karasova (1,2), M.Pohanka (1,3), D.Jun (1,3), K.Kuca (1,3)
(1) University hospital of Hradec Kralove, Czech Republic ; (2) Department of Toxicology ; (3) Center of Advanced Studies, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic ; (4) Department of Radiology and Toxicology, Faculty of Health and Social Studies, University of South Bohemia Ceske Budejovice, Czech Republic

P34 A Novel Neurotrophic Drug For Cognitive Enhancement And Alzheimer’s Disease
M.Prior
Co-authors : Q.Chen, P.Maher, D.Schubert

P35 Correlations of Pharmacokinetic (PK) Measures to Pharmacodynamic (PD) Effects of ELND005 (Scyllo-inositol) from a Phase 2 Dose-Ranging Study in Mild to Moderate Alzheimer’s Disease
E.Liang
Co-authors : J.Wagg, F.Jonsson, J.Cedarbaum, S.Abushakra
POSTERS

Treatment therapeutics for AD (Continued)

P36 Effect of Ratanasampil (Tibet-medicine) on changes of serum -amyloid protein and inflammatory markers in patients with mild to moderate Alzheimer’s disease
A.Zhu
Co-authors : Y.Chu, X.Zhong, G.Li, B.Liao, J.Zhou, S.Gu, M.Yu

P37 Etazolate treatment in a genetic model of Alzheimer disease: rescue of cognitive impairments and physiological biomarkers
D.Colas
Co-authors : Y.Kayo, C.Bayara, H.Grace, H.H.Craig

P38 Title of poster to be announced onsite
R.Shah

Fundamental research on animal models

P39 Are Transgenic Mice Valid Animal Models for the Search for New Treatments for Alzheimer’s Disease (AD)
J.Holtzman
Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, United States

P40 Efficacy Study of Lp-PLA2 Inhibitor -859 in the Hypercholesterolemic Rabbit Model of Alzheimer’s Disease
D.Woodruff-Pak, Neuroscience Program and Psychology Department, Temple University, Philadelphia, PA - USA

Nutrition

P41 The effects of a multi-nutrient drink on functional connectivity in patients with Alzheimer’s disease
M.Lansbergen (2)
Co-authors : H.de Waal (1), E.van Straaten (1), P.Scheltens (1), R.L.Wieggers (2), P.J.Kamphuis (2,3), C.J.Stam (1)
(1) Alzheimer Centre, VU University Medical Centre, Department of Neurology, Amsterdam, The Netherlands ; (2) Nutricia Advanced Medical Nutrition, Danone Research - Centre for Specialised Nutrition, Wageningen, The Netherlands ; (3) Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands

P42 The LipiDiDiet study: rationale and study design
R.Wieggers
Co-authors : Y.Freund-Levi (1), P.J.Visser (2,3), M.Kviriello (4), R.L.Wieggers (5), T.Hartmann (6,7), H.Soininen (8)
(1) Department of NVS, Section of Clinical Geriatrics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden ; (2) Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Netherlands ; (3) Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, Netherlands ; (4) Aging Research Center, Karolinska Institute and Stockholm Gerontology Research Center, Stockholm, Sweden ; (5) Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands ; (6) Deutsches Institut für DemenzPrevention (ديدي), Neurodegeneration and Neurobiology ; (7) Experimental Neurology, Homburg, Germany ; (8) Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
Miscellaneous

P43 Recognition of Facial Expressions and Emotional Prosody in Alzheimer Disease
H. Costa
Co-authors: W. Cristina de Souza

P44 Relationship between patient dependence on others and resource utilization in Alzheimer's disease (AD): results from a longitudinal study
L. Lacey, Janssen Alzheimer Immunotherapy Dublin – Ireland
Co-authors: T. Niecko, C. Leibman, E. Liu, M. Grundman, for the ELN_AIP_901 investigator group
C T A D 2 0 1 1 is being held at the US Grant, a San Diego Icon since 1910, the palatial US GRANT hotel is situated in the city’s lively and historic downtown Gaslamp Quarter with a dazzling array of dining, shopping, nightlife and entertainment venues for all ages. Explore the city’s young heritage and learn about early settlers, including Alonzo Horton and Wyatt Earp at the Gaslamp Quarter Historical Foundation. Your journey can include daytime exploratory tours or an experience within the region’s energetic restaurants and nightlife.

The hotel is easily accessible to San Diego International Airport (15 minutes away) and offers close proximity to the San Diego Cruise Ships terminal, Santa Fe Depot Train Station, as well as the I-5 Freeway. Parking is available at the hotel.

WELCOME RECEPTION
Hosted by the Alzheimer’s Disease Cooperative Study at the University of California San Diego, CTAD2011 welcomes us to an evening of networking and relaxation. Just steps away from Seaport Village, PETCO Park, the famous Gaslamp District and the Convention Center, Roy’s San Diego Waterfront provides the most extraordinary waterfront views in the city.

Buses will depart at 6 pm from the US Grant and return attendees directly to the hotel afterwards.

Roy’s San Diego Waterfront
333 West Harbor Drive
San Diego, CA 92101
REGISTRATION & ACCOMMODATIONS

REGISTRATION AVAILABLE ON LINE: www.ctad.fr

<table>
<thead>
<tr>
<th>EADC member registration fee (1*)</th>
<th>US$ 745</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration fee (1*)</td>
<td>US$ 850</td>
</tr>
</tbody>
</table>

THERE WILL BE NO REGISTRATIONS ONSITE

(1*) Your registration fees include:
- Admission to the full CtaD 2011 conference with all scientific sessions
- Attendee bag with full-program and JNHA review
- Coffee breaks
- Lunch breaks
- Welcome reception

ACCOMMODATIONS: STAY CLOSE TO THE CONFERENCE VENUE!

The US Grant is now sold out but CTaD has negotiated special rates at the Westin Gaslamp across the street from the US Grant, book your room quickly to be sure to secure a hotel room close to the conference venue.

You can book directly on our website: www.ctad.fr
Clinical Trials on Alzheimer’s Disease

Continuing Medical Education

Course Description
The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, drugs in development, and future methodological issues presented in the development of the next generation of Alzheimer’s disease treatments. This year’s topics of discussion include preliminary or new results concerning drug discovery, clinical trials of new therapies in development, methodological issues relating to disease modifying treatments, outcome measurements, biomarkers validation, and health economics.

Target Audience
This conference is designed for neurologists, psychiatrists, geriatric and imaging specialists and physicians interested in finding solutions to the difficulties that have slowed the pace of progress, with a particular focus on clinical trial methodology. Other healthcare professionals who may benefit from this activity are clinical research coordinators, nurses, speech therapists and other AD and dementia occupational therapists, psychologists and neuropsychologists.

Course Objectives
Upon completion of this conference, participants should be able to:
1. Appreciate the full spectrum of AD from an asymptomatic stage through dementia
2. Harmonize neuroimaging methods and analysis for incorporation into trials and clinical practice
3. Elucidate the risk factors for AD and other dementias
4. Identify and avoid methodological errors in the design of multicenter and international clinical trials
5. Use improved measurement of cognitive deficits in their practice
6. Better understand the sequence and relationship among the biochemical and neuroimaging biomarkers of AD

Needs Assessment
The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. Despite major advances in understanding the neurobiology of the disease and identifying plausible therapeutic targets, no new drug has been approved for AD treatment since 2003. The slow progress may have as much or more to do with methodological challenges than with the development of specific drug candidates. This conference brings together world leaders in AD treatment to discuss solutions to the difficulties that have slowed the pace of progress, with a particular focus on clinical trial methodology.

The Scientific committee of this conference has identified practice gaps in the following areas related to the design and conduct of AD clinical trials:

• The need to appreciate the full spectrum of AD from an asymptomatic stage through dementia
• The need for harmonization of neuroimaging methods and analysis for incorporation into trials and clinical practice
• The need to elucidate the risk factors for AD and other dementias
• The need to identify and avoid methodological errors in the design of multicenter and international clinical trials
• The need for improved measurement of cognitive deficits
• The need to clarify the sequence and relationship among the biochemical and neuroimaging biomarkers of AD

Beyond the global practice gaps addressed throughout the conference, other in-depth sessions will cover some specific issues related to the following needs/practice gaps:

• The need to evaluate the relevance of new criteria and their relevance
The need to clarify the issue of Event-Related Potential Biomarkers for Early Diagnosis and Treatment Trials of Alzheimer’s Disease
The need to properly assess the decline in cognitive function, which is the key change heralding the onset of mild cognitive impairment and dementia in Alzheimer’s disease (AD)
The need to clarify the weight, quality and reliability of the evidence in conversion from MCI to dementia in AD
The need to improve measurement methodology to detect treatment effect in clinical trials

Accreditation Statement
The University of California, San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The University of California, San Diego School of Medicine designates this live activity for a maximum of 18.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural and Linguistic Competency Statement
California Assembly Bill 1195 requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. It is the intent of the bill, which went into effect on July 1, 2006, to encourage physicians and surgeons, CME providers in the state of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population through appropriate professional development. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area. In addition, a variety of resources are available that address cultural and linguistic competency, some of which may be included in your syllabus or handout materials. Additional resources and information about AB1195 can be found on our website at http://cme.ucsd.edu.
<table>
<thead>
<tr>
<th>Course Directors</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul S. Aisen, MD</td>
<td>Alzheimer's Disease Cooperative Study (ADCS)</td>
<td>Department of Neurosciences</td>
<td>UCSD School of Medicine</td>
</tr>
<tr>
<td>Jacques Touchon, MD, PhD</td>
<td>Chair of the Department of Neurology</td>
<td>Montpellier University Hospital</td>
<td>France</td>
</tr>
<tr>
<td>Bruno Vellas, MD, PhD</td>
<td>Toulouse University Hospital</td>
<td>Department of Neurology</td>
<td>Toulouse, France</td>
</tr>
<tr>
<td>UC San Diego</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M. Colin Ard, PhD</td>
<td>Department of Neurosciences</td>
<td>UCSD School of Medicine</td>
<td></td>
</tr>
<tr>
<td>Steven D. Edland, PhD</td>
<td>Data Management and Statistics</td>
<td>Department of Neurosciences</td>
<td>UCSD School of Medicine</td>
</tr>
<tr>
<td>Douglas Galasko, MD</td>
<td>Department of Neurosciences</td>
<td>UCSD School of Medicine</td>
<td></td>
</tr>
<tr>
<td>Adam S. Fleisher, M.D., M.A.S.</td>
<td>Associate Professor, Department of Neurosciences University of California, San Diego</td>
<td>Associate Director of Brain Imaging Banner Alzheimer's Institute Medical Director, Alzheimer’s Disease Cooperative Study</td>
<td></td>
</tr>
<tr>
<td>Dominic Holland</td>
<td>Alzheimers Disease Neuroimaging Initiative</td>
<td>UCSD School of Medicine</td>
<td></td>
</tr>
<tr>
<td>Visiting Faculty</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sandrine Andrieu, MD, PhD</td>
<td>Toulouse University Hospital</td>
<td>Department of Neurology</td>
<td>Toulouse, FRANCE</td>
</tr>
<tr>
<td>Alireza Atri, M.D., Ph.D.</td>
<td>Memory Disorders Unit</td>
<td>Massachusetts General Hospital</td>
<td>MIND Brain Laboratory</td>
</tr>
<tr>
<td>Laura Baker, MD</td>
<td>Assistant Professor of Psychiatry &amp; Behavioral Sciences, University of Washington School of Medicine</td>
<td>Seattle, WA</td>
<td>USA</td>
</tr>
<tr>
<td>Adam Boxer, MD</td>
<td>University of California San Francisco</td>
<td>San Francisco, CA</td>
<td>USA</td>
</tr>
<tr>
<td>Andrew E. Bud Hudson, MD</td>
<td>Professor of Neurology</td>
<td>Boston University</td>
<td>Associate Director, ADC Research</td>
</tr>
<tr>
<td>Boston VA Medical Center</td>
<td>Boston, MA</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Cynthia Carlsson, MD</td>
<td>Department of Medicine</td>
<td>University of Wisconsin</td>
<td>Madison, WI</td>
</tr>
<tr>
<td>United States</td>
<td>Jeff Cummings, MD</td>
<td>Cleveland Clinic Lou Ruvo Brain Institute</td>
<td>Las Vegas, NV</td>
</tr>
<tr>
<td>USA</td>
<td>Rachelle S. Doody, MD, PhD</td>
<td>Effie Marie Cain Chair in Alzheimer’s Disease Research</td>
<td>Director, Alzheimer's Disease and Memory Disorders Center</td>
</tr>
<tr>
<td>Houston, Texas, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bruno Dubois, MD, PhD</td>
<td>Neurological Institute, University Salpetriere Hospital</td>
<td>Paris, France</td>
<td></td>
</tr>
<tr>
<td>Howard Feldman, MD</td>
<td>Global Clinical Research, Neuroscience</td>
<td>Bristol Myers Squibb</td>
<td>New York, NY</td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Audrey Gabelle, MD</td>
<td>Department of Neurology, Memory center, University Hospital Gui de Chauliac</td>
<td>Montpellier</td>
<td>FRANCE</td>
</tr>
<tr>
<td>Lidia Gliotzki, MD</td>
<td>Department of Psychiatry (Ctr of Brain Health)</td>
<td>NYU Langone Medical Center</td>
<td>New York, NY</td>
</tr>
<tr>
<td>USA</td>
<td>Michael Gold, MD</td>
<td>Allon Therapeutics</td>
<td>Vancouver, BC</td>
</tr>
<tr>
<td>Canada</td>
<td>Paula Grammas, MD</td>
<td>Garrison Institute on Aging, Texas Tech University Health Science Center</td>
<td>Lubbock, TX</td>
</tr>
<tr>
<td>USA</td>
<td>Suzanne Hendrix, PhD</td>
<td>Pentara Corporation</td>
<td>Salt Lake City, UT</td>
</tr>
<tr>
<td>USA</td>
<td>Edward Herskovits, MD</td>
<td>Department of Radiology, University of Pennsylvania, Philadelphia, PA</td>
<td>USA</td>
</tr>
<tr>
<td>William Hu, MD, PhD</td>
<td>Alzheimer’s Disease Research Center</td>
<td>Emory University</td>
<td>Atlanta, GA</td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Faculty List

Edward (Ted) Huey, MD
Departments of Psychiatry and Neurology
Columbia University
New York, NY
USA

Stella Karantzoulis, PhD
Center of Excellence on Brain Aging
New York University Langone Medical Center,
New York, NY
USA

Jeffrey Kaye, MD
Professor of Neurology and Biomedical Engineering
Director, NIA - Layton Aging & Alzheimer’s Disease Center
Director, NIA - ORCATECH - Oregon Center for Aging & Technology
Oregon Health & Science University and Portland Veterans Affairs
Portland, Oregon USA

David Knopman, MD
Neurology
Mayo Clinic,
Rochester, MN
USA

Amos D. Korczyn, MD PhD
Sieratcki Chair of Neurology
Tel-Aviv University Medical School
Ramat Aviv, Israel

Joel Kramer, MD
Neurology
University of California, San Francisco
San Francisco, CA
USA

Richard Kryscio, MD
Sanders-Brown Center on Aging
University of Kentucky
Lexington, KY
USA

Jessica Langbaum, PhD
Banner Alzheimer’s Institute
USA

Brian Lawlor, MD
St. James’s Hospital,
Dublin, Ireland

Christopher Leibman, PharmD, MS
Janssen Alzheimer Immunotherapy
USA

Steven Leiser, PhD,
Lundbeck Research
USA

William R. Lenderking, PhD
Senior Research Scientist
Center for Health Outcomes Research
United BioSource Corporation
USA

José A. Luchsinger, MD MPH
Associate Professor of Medicine and Epidemiology
at New York Presbyterian Hospital/Columbia University Medical Center
Northern Manhattan Center of Excellence in Minority Health and Health
Disparities (NCEMHD) at Columbia University
Division of General Medicine
New York, NY USA

Constantine G. Lyketsos, MD
Chair of Psychiatry, Johns Hopkins Bayview
Vice Chair of Psychiatry, Johns Hopkins Medicine
Baltimore, MD
USA

Ian Mackenzie, MD
University of British Columbia
Vancouver, BC
Canada

Rupert McShane, MD
Cochrane Dementia and Cognitive Improvement Group
University of Oxford
United Kingdom

David Miller, MD
Therapeutic Area
Bracket global Co.
USA

Anna Noel-Storr, MD
Cochrane Dementia and Cognitive Improvement Group
University of Oxford
United Kingdom

John Olichney, MD,
Neurology department
University of California Davis
USA

Pierre-Jean Ousset, MD
Centre Mémoire - Gérontopôle
Memory Clinic - Toulouse University Hospital
France

Oliver Peters, MD Department of Psychiatry,
Charitè-CBF,
Berlin
GERMANY

Ronald C. Petersen, M.D., Ph.D.
Mayo Alzheimer’s Disease Research Center
Mayo Clinic
Rochester, MN
USA

Anton P. Porsteinsson M.D.
William B. and Sheila Konar Professor of Psychiatry
Director, Alzheimer’s Disease Care, Research and Education Program
(AD-CARE)
Director, Memory Disorders Clinic
University of Rochester School of Medicine
Rochester, N.Y.
USA

Terry Quinn, MD
Cochrane Dementia and Cognitive Improvement Group,
University of Glasgow
Glasgow, Scotland
United Kingdom

Jacob Raber, PhD
Oregon Health and Science University
Portland, Oregon USA

Nandini Raghavan, PhD
Johnson and Johnson Research
Raritan NJ,
USA

Ruth Remington, PhD
University of Massachusetts Lowell
Lowell, MA
USA
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthias Riepe, MD, PhD</td>
<td>Department of Geriatrics and Psychiatry</td>
<td>G&quot;unzburg, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Howard Rosen, MD</td>
<td>Neurology</td>
<td>San Francisco, CA</td>
<td>USA</td>
</tr>
<tr>
<td>Allen Roses, MD</td>
<td>Duke University School of Medicine</td>
<td>Durham, NC</td>
<td>USA</td>
</tr>
<tr>
<td>Stephen Salloway, M.D., M.S.</td>
<td>Director of Neurology and the Memory and Aging Program, Butler Hospital</td>
<td>United States</td>
<td>USA</td>
</tr>
<tr>
<td>Cristina Sampaio, MD, PhD</td>
<td>Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Lisbon</td>
<td>Portugal</td>
<td></td>
</tr>
<tr>
<td>Mary Sano, PhD</td>
<td>Director, Alzheimer Disease Research Center</td>
<td>Bronx NY, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Philip Scheltens, MD, PhD</td>
<td>Alzheimer Centrum en afd. Neurologie</td>
<td>VU Medisch Centrum</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Achim Schneeberger, MD, PhD</td>
<td>AFFIRIS AG</td>
<td>Vienna, Austria</td>
<td></td>
</tr>
<tr>
<td>Lon Schneider, MD, PhD</td>
<td>Alzheimer’s Disease Research and Clinical Center</td>
<td>Los Angeles, CA</td>
<td>USA</td>
</tr>
<tr>
<td>Maria Segerdhal, MD, PhD</td>
<td>Medical Sciences</td>
<td>Sodertalje, Sweden</td>
<td></td>
</tr>
<tr>
<td>William R. Shankle, MD MD FACp</td>
<td>Shankle Clinic</td>
<td>Newport Beach, CA</td>
<td>USA</td>
</tr>
<tr>
<td>Koichi Shudo, MD</td>
<td>Research Foundation</td>
<td>Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td>Nadja Smailagic, MD</td>
<td>Cochrane Dementia and Cognitive Improvement Group, University of Cambridge</td>
<td>Cambridge, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>David Smith, MD</td>
<td>OPTIMA</td>
<td>University of Oxford</td>
<td>Oxford, United Kingdom</td>
</tr>
<tr>
<td>Reisa Sperling, M.D.</td>
<td>Associate Professor of Neurology, Harvard Medical School</td>
<td>Brigham and Women’s Hospital</td>
<td>Boston, MA, USA</td>
</tr>
<tr>
<td>René Spiegel, MD</td>
<td>Memory Clinic,</td>
<td>University Hospital</td>
<td>Basel, Switzerland</td>
</tr>
<tr>
<td>Joyce Suhy, MD</td>
<td>Synarc</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Pierre Tariot, MD</td>
<td>Banner Alzheimer’s Institute</td>
<td>Phoenix, AZ</td>
<td>USA</td>
</tr>
<tr>
<td>Christopher van Dyck, MD</td>
<td>Alzheimer’s Disease Research Unit,</td>
<td>New Haven, CT</td>
<td>USA</td>
</tr>
<tr>
<td>Diana Woodruff-Pak, PhD</td>
<td>Neuroscience Program and Psychology Department,</td>
<td>Temple University</td>
<td>Philadelphia, PA, USA</td>
</tr>
<tr>
<td>Christopher van Dyck, MD</td>
<td>Alzheimer’s Disease Research Unit,</td>
<td>New Haven, CT</td>
<td>USA</td>
</tr>
<tr>
<td>Mary Sano, PhD</td>
<td>Director, Alzheimer Disease Research Center</td>
<td>Bronx NY, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Stephen Salloway, M.D., M.S.</td>
<td>Director of Neurology and the Memory and Aging Program, Butler Hospital</td>
<td>United States</td>
<td>USA</td>
</tr>
<tr>
<td>Cristina Sampaio, MD, PhD</td>
<td>Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Lisbon</td>
<td>Portugal</td>
<td></td>
</tr>
<tr>
<td>Mary Sano, PhD</td>
<td>Director, Alzheimer Disease Research Center</td>
<td>Bronx NY, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Philip Scheltens, MD, PhD</td>
<td>Alzheimer Centrum en afd. Neurologie</td>
<td>VU Medisch Centrum</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Achim Schneeberger, MD, PhD</td>
<td>AFFIRIS AG</td>
<td>Vienna, Austria</td>
<td></td>
</tr>
<tr>
<td>Lon Schneider, MD, PhD</td>
<td>Alzheimer’s Disease Research and Clinical Center</td>
<td>Los Angeles, CA</td>
<td>USA</td>
</tr>
<tr>
<td>Maria Segerdhal, MD, PhD</td>
<td>Medical Sciences</td>
<td>Sodertalje, Sweden</td>
<td></td>
</tr>
<tr>
<td>William R. Shankle, MD MD FACp</td>
<td>Shankle Clinic</td>
<td>Newport Beach, CA</td>
<td>USA</td>
</tr>
<tr>
<td>Koichi Shudo, MD</td>
<td>Research Foundation</td>
<td>Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td>Nadja Smailagic, MD</td>
<td>Cochrane Dementia and Cognitive Improvement Group, University of Cambridge</td>
<td>Cambridge, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>David Smith, MD</td>
<td>OPTIMA</td>
<td>University of Oxford</td>
<td>Oxford, United Kingdom</td>
</tr>
<tr>
<td>Reisa Sperling, M.D.</td>
<td>Associate Professor of Neurology, Harvard Medical School</td>
<td>Brigham and Women’s Hospital</td>
<td>Boston, MA, USA</td>
</tr>
<tr>
<td>René Spiegel, MD</td>
<td>Memory Clinic,</td>
<td>University Hospital</td>
<td>Basel, Switzerland</td>
</tr>
<tr>
<td>Joyce Suhy, MD</td>
<td>Synarc</td>
<td></td>
<td>USA</td>
</tr>
</tbody>
</table>
Disclosure summary (as of October 7, 2011)

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

<table>
<thead>
<tr>
<th>Speaker Name</th>
<th>Name of Commercial Interest</th>
<th>Nature of Relevant Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jerome Barakos</td>
<td>Synarc</td>
<td>Consultant</td>
</tr>
<tr>
<td>Adam Boxer</td>
<td>Allon therapeutics, BMS</td>
<td>Grant/contract, consultant</td>
</tr>
<tr>
<td>Jeffrey Cummings</td>
<td>- Abbott, Acadia, Acerra, ADAMAS, Anavex, Astellas, Avanir, Baxter, Bristol-Myers Squibb,</td>
<td>Consultant for pharmaceutical companies</td>
</tr>
<tr>
<td></td>
<td>Eisai, Elan, EnVivo, Forest, Genentech, GlaxoSmithKline, Janssen, Lilly, Lundbeck, Medivation, Medtronic, Merck, Merz, Neurokos, Novartis, Pfizer, Prana, QR, Sonexa, Takeda, and Toyama</td>
<td>Consultant for assessment companies</td>
</tr>
<tr>
<td></td>
<td>- Bayer, Avid, GE, MedAvante, Neurotrax, and UBC</td>
<td>Speaker/lecturer</td>
</tr>
<tr>
<td></td>
<td>- ADAMAS, Prana, Sonexa, MedAvante, Neurotrax, Neurokos, and QR pharma</td>
<td>Copyright owner</td>
</tr>
<tr>
<td></td>
<td>- Eisai, Forest, Janssen, Novartis, Pfizer, Lundbeck.</td>
<td>Expert witness/legal consultation with expertise in drug development</td>
</tr>
<tr>
<td></td>
<td>- Neuropsychiatric Inventory</td>
<td>regarding olanzapine and ropinerol.</td>
</tr>
<tr>
<td></td>
<td>- other</td>
<td></td>
</tr>
<tr>
<td>Rachelle Doody</td>
<td>Pfizer, UBC</td>
<td>- Baylor has contracts for two clinical trials for which I am PI. I provided one consultation to the company related to global drug development. - Consultant on the development of patient reported outcomes</td>
</tr>
<tr>
<td>Bruno Dubois</td>
<td>Eisai</td>
<td>Consultant</td>
</tr>
<tr>
<td>Steven D. Edland</td>
<td>Eli Lilly</td>
<td>Data monitoring Board</td>
</tr>
<tr>
<td>Howard Feldman</td>
<td>BMS</td>
<td>Full-time employee</td>
</tr>
<tr>
<td>Adam Fleisher</td>
<td>Avid, Lilly</td>
<td>Partial grant funding for project presented</td>
</tr>
<tr>
<td>Steven C. Leiser</td>
<td>Lundbeck research</td>
<td>Consultant</td>
</tr>
<tr>
<td>William Linderking</td>
<td>UBC</td>
<td>Employee</td>
</tr>
</tbody>
</table>
# Disclosure summary

<table>
<thead>
<tr>
<th>Speaker Name</th>
<th>Name of Commercial Interest</th>
<th>Nature of Relevant Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Miller</td>
<td>Bracket (part of UBC)</td>
<td>Full-time employee</td>
</tr>
<tr>
<td>Anton P. Porsteinsson, MD</td>
<td>Baxter, BMS, Elan, Genentech/Roche, Janssen Alzheimer Initiative, Medivation, Pfizer, Toyama Elan, Janssen Alzheimer Initiative, Medivation, Pfizer, Transition Therapeutics Forest</td>
<td>Consultant/Research Support</td>
</tr>
<tr>
<td>Nandini Raghavan</td>
<td>Johnson and Johnson</td>
<td>Employee and shareholder</td>
</tr>
<tr>
<td>Matthias Riepe</td>
<td>Eisai, Elan, Janssen, Lundbeck, Merz, Novartis, Pfizer, Wyeth</td>
<td>Grants/honoraria for dementia-related work</td>
</tr>
<tr>
<td>Allen David Roses</td>
<td>Eli Lilly, Takeda Pharma, Zinfindel</td>
<td>Research support</td>
</tr>
<tr>
<td>Lon S. Schneider</td>
<td>Pfizer, Novartis Johnson and Johnson</td>
<td>Consultant</td>
</tr>
<tr>
<td>Märtä Segerdhal</td>
<td>AstraZeneca</td>
<td>Employee</td>
</tr>
<tr>
<td>William R. Shankle</td>
<td>Medical Care Corporation</td>
<td>Employee, Board Member, Stock Shareholder</td>
</tr>
<tr>
<td>Reisa Spierling</td>
<td>Pfizer, BMS, Roche, Janssen, Eisai</td>
<td>Consultant</td>
</tr>
<tr>
<td>Pierre Tariot</td>
<td>Acadia, AC Immune, Allergan, Eisai, Inc, Genentech, Medavante, Novartis, sanofi aventis, Schering-Plough, Abbott Laboratories, AstraZeneca, Avid, Bristol Myers Squibb, Élan, GlaxoSmithKline, Eli Lilly, Medivation, Merck and Company, Pfizer Inc., and Wyeth Laboratories</td>
<td>Consultant</td>
</tr>
<tr>
<td>Christopher H. van Dyck</td>
<td>- Bristol-Myers Squibb, Pfizer Inc, Janssen AI, Elan Pharmaceuticals, GlaxoSmithKline - Eli Lilly, Baxter Pharmaceuticals, Medivation, Genentech</td>
<td>Consultant/Scientific Advisory Grants/Research Support</td>
</tr>
</tbody>
</table>

The following have no relevant financial relationships to disclose:

The CME staff, meeting planners, planning committee and CME committee reviewers do not have any relevant financial relationships to disclose.

This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.
Clinical Trials on Alzheimer’s Disease (CTAD) would like to thank the following companies for their ongoing support helping CTAD meet its mission and goals.

Bristol-Myers Squibb
Eisai
IPSEN
Innovation for patient care

ALZHEIMER’S IMMUNOTHERAPY PROGRAM
INNOVATION TO REMEMBER™

Pfizer

Lundbeck
Novartis
Clinical Trials on Alzheimer's Disease

October 29-31, 2012
Monte Carlo

http://www.ctad.fr